Follicular lymphoma
Conditions
Interventions
ZG—CHOP treatment group:Patients were treated with zanubrutinib combined with the G-CHOP regimen (zanubrutinib:160mg, po bid, d1-d21
obinutuzumab: 1000 mg, iv, d1, d7, d14 for first cycle, d1 for other cycles
cyclophosphamide: 750mg/m^2, iv, d1
doxorubicin:50 mg/m^2, iv, d1
vincristine: 1.4mg/m^2 (maximum 2mg), iv, d1
and prednisone: 100mg, po, d1-5), administered every 3 weeks for a total of 6 cycles. Patients who completed the treatment course and achieved remission would enter the maintenance treatment phase, re
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients fully understand this study, voluntarily participate in and sign the informed consent form; 2. Age is >=18, =2 points); 5. No prior treatment for follicular lymphoma, including chemotherapy, immunotherapy, targeted therapy, local radiotherapy for lymphoma (except for local radiotherapy for alleviating tumor-related symptoms); 6. According to the 2014 lugano evaluation criteria for lymphoma, at least one CT/MRI measurable lesion (lymph node length > 1.5cm, extranodal lesion length diameter >1.0cm); 7. The function of major organs meets the following criteria: absolute neutrophil value >=1.0×10^9/L, platelet count >=75×10^9/L, hemoglobin >=80g/L, serum creatinine =50ml/min, left ventricular ejection fraction (LVEF) >=50%; 8. Expected survival >=3 months; 9. For males or females of childbearing potential who have not undergone sterilization surgery, agreement to use effective contraception during treatment and for 12 months after the last dose of study drug.
Exclusion criteria
Exclusion criteria: 1.Patients with follicular lymphoma transforming to diffuse large B-cell lymphoma; 2.Patients with tumor central nervous system infiltration; 3.Patients who are unable to swallow the capsule or have a medical condition that significantly affects gastrointestinal function, or who have a history of allergy to similar drugs and excipients of the investigational drug; 4.Patient has other active malignancies and other hematological diseases that require concurrent treatment; 5.Patients have an uncontrolled, active systemic fungal, bacterial, viral, or other infection; 6.Patients with significant and uncontrolled cardiovascular disease; 7.Patients with uncontrolled HBV or HCV infection (HBV surface antigen positive and/or HBV core antibody positive with more than 1×10^3 copies /mL of HBV DNA; More than 1×10^3 copies of HCV RNA /mL); 8.Patients with any life-threatening disease, medical condition, or organ system dysfunction that the investigator believes may affect the safety of the subject or pose a risk to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;CR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety; | — |
Countries
China
Contacts
Public ContactHaisheng Liu
The Fourth Hospital of Hebei Medical University
Outcome results
None listed